I. R. Bell, J. S. Edman, F. D. Morrow, D. W. Marby, G. Perrone, H. L. Kayne, M. Greenwald and J. O. Cole, “Vitamin B1, B2, and B6 Augmentation of Tricyclic Antidepressant Treatment in Geriatric Depression with Cognitive Dysfunction,” American Journal of Clinical Nutrition, Vol. 11, No. 2, 1992, pp. 159-163.

has been cited by the following article:

• TITLE: The Impact of Thiamine Treatment on Generalized Anxiety Disorder

  AUTHORS: Khanh vinh quốc Lương, Lan Thi Hoàng Nguyễn

  KEYWORDS: Thiamine, General Anxiety Disorder, Vitamin B1, Anxiety

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.2 No.4, September 30, 2011

  ABSTRACT: Objective: Patients with generalized anxiety disorder (GAD) are fearful. They constantly worried about minor matters, and they anticipate the worst. The GAD is diagnosed when a patient experiences excessive anxiety and worry for at least 6 months. The cause of GAD is unknown. In the present paper, we discuss patients with GAD who have low levels of thiamine in their bloods. We also discuss the role of thiamine in the pathogenesis and treatment of GAD. Methods: We examined 9 patients (6 males and 3 females) who met the DSM-IV-TR diagnostic criteria for GAD. These patients had no history of alcoholism. Their ages ranged from 57 to 83 years old (mean age –72.8 ± 2.9 years). All of the patients had low blood thiamine levels (mean –25.1 nmol/L ± 6.0 nmol/L; normal level—70 nmol/L - 180 nmol/L). Participants completed the Hamilton Anxiety Rating Scale (HARS) for anxiety before and after thiamine treatments. All of the patients received daily thiamine 100 mg intramuscularly. Results: Thiamine supplementation significantly improved HARS scores, increased both appetite and general well-being, and reduced fatigue in patients with GAD. Interestingly, these patients were able to discontinue taking anxiolytic and β-blocker medications. Conclusion: Parental thiamine significantly affects patients with GAD.